$TMO

CASPER MARC N sold $5.8M of TMO

CASPER MARC N (Chairman & CEO) sold 10,000 shares of THERMO FISHER SCIENTIFIC INC. (TMO) at an average of $575.23 ($566.25–$577.56, $5.75M total) across 11 trades on 2026-08-05 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · CASPER MARC N
Published Aug 7, 2026, 9:26 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 7, 2026, 9:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$TMO
Neutral
medium confidence
Mentioned
$TMO
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TMONeutralLow
01

Why it matters

The key tradable takeaway is the disclosed magnitude and timing of insider selling, which can influence short-term sentiment but is less informative about near-term fundamentals due to the 10b5-1 structure.

02

Market read

A $5.75M CEO/Chairman open-market sale under a 10b5-1 plan is disclosed, which may slightly pressure sentiment but is unlikely to drive a major repricing alone.

03

What to watch

The filing does not state tax, diversification, or personal liquidity needs; traders should avoid over-weighting the signal without corroborating fundamentals or additional insider activity.

Relevance 5/10Novelty 5/10Timing: Form 4 filed 2026-08-07, covering sales executed 2026-08-05.

Background

This is an SEC Form 4 insider transaction for Thermo Fisher Scientific, reported by its Chairman and CEO under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$TMONeutralMedium confidence
Context

Thermo Fisher CEO and Chairman Casper Marc N sold $5.75M of TMO shares via an open-market sale under a 10b5-1 plan on 2026-08-05.

Expected impact

Likely limited, short-lived impact unless paired with other company-specific news.

Evidence & confidence

The filing is a primary Form 4 disclosure, but it specifies a pre-arranged 10b5-1 plan and provides no accompanying operational or guidance change.

Market effects

Minimal sector read-through; this is company-specific insider activity without stated business developments.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a 10b5-1 plan, it may reflect routine liquidity/compensation rather than bearish expectations.

Key entities

  • THERMO FISHER SCIENTIFIC INC.

    Subject of the Form 4 insider sale by its Chairman and CEO.

  • CASPER MARC N

    Chairman & CEO who executed the open-market sale of TMO shares.

Related articles

$TMOMedAI 8/10

Thermo Fisher (TMO) Climbs 8.7% on Solid Earnings, Price Target Upgrades

Thermo Fisher Scientific (TMO) shares rose 8.71% to close at $572.32 after Q2 results. Net income increased 7% to $1.736B and revenue rose 10% to $11.99B, according to the company. Jefferies, Leerink Partners, and Evercore ISI raised price targets to $630, $620, and $615. The board authorized a $0.47 dividend per share.

$TMOMed

Thermo Fisher TMO Stock Draws Bullish Calls Ahead Of Q2

Thermo Fisher Scientific (TMO) shares rose about 9% after upbeat earnings and guidance, with the stock moving roughly from $501 to $574. Deutsche Bank reiterated a Buy and set a $630 target; Baird raised its target to $652. The company also announced an Arcturus collaboration on ARCT-032 and reaffirmed a $0.47 quarterly dividend.